ImmunoMolecular Therapeutics is a private clinical stage biotech company developing a revolutionary therapeutic approach for the treatment of Type I Diabetes. The company was founded by world class researchers at the Barbara Davis Center for Diabetes. The company’s proprietary approach to Type I Diabetes interrupts the body’s autoimmune processes that destroy pancreatic beta cells in diabetic patients. By interrupting these autoimmune processes, the patient maintains the ability to produce insulin normally. The approach has applications in other diseases related to the body’s autoimmune processes.